About: Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA)
Creator	Nguyen, Minh Fernandez-Gutierrez, Benjamín Pablos, Jose Rodriguez-Rodriguez, Luis Baillet, Athan Balsa, Alejandro Freites-Núñez, Dalifer Gaudin, Philippe Gonzalez, Isidoro Vazquez, Monica
Source	PMC
abstract	BACKGROUND: Rheumatoid arthritis (RA) is one of the leading chronic inflammatory rheumatism. First-line therapy with synthetic disease-modifying antirheumatic drugs (sDMARD) is insufficiently effective in 40% of cases and these patients are treated with biotherapies. The increased use of these drugs each year is becoming a public health issue with considerable economic burden. This cost is 20 times higher than that of sDMARD. However, among patients treated with biotherapies, clinical practice shows that about one third will not respond to the selected drug. In nonresponse cases, practitioners currently have no choice but to perform an empirical switching between different treatments, because no tool capable of predicting the response or nonresponse to these molecules is currently available. METHODS: The study is a prospective, phase III, controlled, multicenter, and randomized, single-blind (patient) clinical trial, including RA patients with a previous failure to anti-TNF therapies. The main objective is the analysis of the clinical and pharmacoeconomic impact after 6 months of treatment. Intervention arm: prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest® software, a prediction software based on proteomic biomarkers. Control arm: prescription of biotherapy based on current practice, without the SinnoTest® software (any biotherapy). In addition, a substudy will be carried out within this trial to generate a biobank and further analyze the proteomic profile of the patients and their modification throughout the study. DISCUSSION: This clinical trial study will be the first validation study of a biotherapy response prediction software, bringing personalized medicine into the management of RA. We expect that the findings from this study will bring several benefits for the patient and the Health Care System. TRIAL REGISTRATION: ClincalTrials.gov NCT04147026. Registered on 31 October, 2019.
has issue date	2020-08-31(xsd:dateTime)
bibo:doi	10.1186/s13063-020-04683-7
has license	cc-by
schema:url	https://doi.org/10.1186/s13063-020-04683-7
resource representing a document's title	Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA)
has PubMed Central identifier	PMC7456748
schema:publication	Trials
resource representing a document's body	covid:PMC7456748#body_text
is schema:about of	named entity 'multicenter' named entity 'predictive model' named entity 'biologic agent' named entity 'blood sample' named entity 'biosimilars' named entity 'rituximab' named entity 'intraarticular' named entity 'CD20' named entity 'anakinra' named entity 'pharmacoeconomic' named entity 'curriculum vitae' named entity 'infliximab' named entity 'urinary infections' named entity 'rheumatologist' named entity 'EULAR' named entity 'research staff' named entity 'DAS28' named entity 'confidence intervals' named entity 'acute phase reactants' named entity 'adalimumab' named entity 'corticosteroids' named entity 'etanercept' named entity 'pregnancy' named entity 'certolizumab' named entity 'genomics' named entity '2019 Euros' named entity 'ClinicalTrials.gov' named entity 'missing data' named entity 'biomarkers' named entity 'rheumatologists' named entity 'EQ-5D' named entity 'Informed consent' named entity 'biological assay' named entity 'principal investigator' named entity 'sensitivity analysis' named entity 'rheumatologist' named entity 'France' named entity 'clinical practice' named entity 'rheumatologist' named entity 'DMARD' named entity 'protein' named entity 'QALY' named entity 'epigenetics' named entity 'clinical trial' named entity 'pharmacoeconomic' named entity 'biobanks' named entity 'indirect costs' named entity 'clinical history' named entity 'biosimilars' named entity 'pharmaceutical companies' named entity 'Sensitivity, specificity' named entity 'medical device' named entity 'toxicity' named entity 'standard deviation' named entity 'proteomic' named entity 'contraindicated' named entity 'multiple sclerosis' named entity 'biobank' named entity 'Biobank' named entity 'adalimumab' named entity 'rheumatology' named entity 'study drugs' named entity 'disease-modifying antirheumatic drugs' named entity 'comorbidity' named entity 'receptor' named entity 'corticosteroids' named entity 'biotherapy' named entity 'randomization' named entity 'clinical evaluation' named entity 'occupational therapist' named entity 'biotherapy' named entity 'research staff' named entity 'biotherapy' named entity 'hypotension' named entity 'control group'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software